Short Bowel Syndrome Market Size, Share And Top Companies Ardelyx, Emmaus Life Sciences, GLyPharma Therapeutic, Merck KGaA, Naia Pharmaceuticals

Coherent Market Insights has announced the addition of the “Short Bowel Syndrome Market Size Status and Forecast 2026”, The report classifies the global Short Bowel Syndrome Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth.

This report studies the global Short Bowel Syndrome Market Speaker market, analyzes and researches the Short Bowel Syndrome Market Speaker development status and forecast in North America, Europe, Asia Pacific, Latin America and Rest of the World. This report focuses on the top players in global market, like Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals

Get PDF for more Professional and Technical insights@ www.coherentmarketinsights.com/insight/request-sample/169

GLP-2 drug class dominates the leading markets in North America and Europe

The global short bowel syndrome market is segmented on the basis of drug class and geography. On the basis of drug class, the market is divided into GLP-2, growth hormone, glutamine and others.

Increasing prescription of Gattex Therapy for Short Bowel Syndrome in North America creates a highly lucrative prospect for growth

Regional segmentation of the short bowel syndrome market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. North America accounts for the largest share in global market, mainly due to presence of major players and early adoption of advanced medical technologies in countries such as the U.S. and Canada. According to National Institute of Diabetes and Digestive and Kidney Disease, in 2008, there were more than 2,000 intestinal transplantations performed in the U.S., out of which 75% population was of the age group of 18-20 years. These numbers are expected to increase year on year, which would inadvertently fuel growth of the short bowel syndrome market.

Key players in the global short bowel syndrome market

Key players operating the short bowel syndrome market include Ardelyx, Inc., Emmaus Life Sciences, Inc., GLyPharma Therapeutic, Inc., Merck KGaA, Naia Pharmaceuticals, Inc., Nutrinia Ltd., OxThera, Sancilio & Company, Inc., Shire plc, and Zealand Pharma A/S. Major companies in the short bowel syndrome industry are constantly working towards introducing innovative products and lowering production costs in order to enhance profitability. For instance, Nutrinia Ltd. plans to begin a critical clinical trial on a drug for short bowel syndrome, which will aid thousands of patients globally by reducing their dependence on parenteral nutrition is the major cause of liver infection.

Download the PDF brochure: www.coherentmarketinsights.com/insight/request-pdf/169

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.